Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Novo Nordisk is escalating its obesity strategy at a time when competition with Eli Lilly is becoming more intense, pricing pressure is rising, and the long-term exclusivity of semaglutide is beginning to weaken in some markets.</li><li>Its latest move is a licensing agreement worth up to $2.6 billion for HRS-1596, an experimental oral GLP-1/GIP drug from Jiangsu Hengrui Pharmaceuticals that could eventually be taken once weekly.</li><li>Only $300 million is being paid upfront, with the balance tied to future development and commercial milestones, but the transaction still highlights how aggressively Novo is searching for the next generation of obesity treatments.</li></ul>

Novo Nordisk is escalating its obesity strategy at a time when competition with Eli Lilly is becoming more intense, pricing pressure is rising, and the long-term exclusivity of semaglutide is beginning to weaken in some markets.Its latest move is a licensing agreement worth up to $2.6 billion for HRS-1596, an experimental oral GLP-1/GIP drug from Jiangsu Hengrui Pharmaceuticals that could eventually be taken once weekly.Only $300 million is being paid upfront, with the balance tied to future development and commercial milestones, but the transaction still highlights how aggressively Novo is searching for the next generation of obesity treatments.

Novo Nordisk’s $2.6 Billion Obesity Bet: Can It Catch Eli Lilly Again?